Company intelligence / Profile preview

Shanghai Huilun

Shanghai, Shanghai, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Huilun Pharma is a China-based pharmaceutical company focused on the research, development, and commercialization of small molecule innovative drugs and high-end generic medicines. The company maintains a robust pipeline targeting oncology, metabolic diseases, and inflammatory conditions, with a particular emphasis on PARP inhibitors and SGLT2 inhibitors. Huilun Pharma operates integrated R&D centers and manufacturing facilities that comply with international GMP standards. By leveraging its internal chemistry expertise, the company aims to provide affordable and effective therapeutic solutions for patients in China and global markets.

Therapeutic areas: CardiovascularOncologyImmunologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Huilun.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Huilun.

Explore the full profile